Cytodyn Shareholders Community Michael Fumelle
Post# of 157652
(Total Views: 414)
Posted On: 10/05/2025 10:55:16 AM
Cytodyn Shareholders Community
Michael Fumelle
·
October 1 at 9:54 AM
·
Geoffrey Fourqurean’s Post from LinkedIn
View profile for Geoffrey Fourqurean
Geoffrey Fourqurean
Neuroscientist, Returned Peace Corps Volunteer, Polyglot, poet, Alumnus: AstraZeneca, GlaxoSmithKline, Neurocrine Biosciences, ex-Gilead, Chief Consultant, Patient Advocate, Biotech Industry Analyst, ESMO Member, Author
1d
A major new review just landed in the *International Journal of Biological Macromolecules* — and it’s a big deal.
Title: **“C–C motif glycoprotein ligand 5 (CCL5) and its GPCR CCR5: Macromolecular game-changers in cancer biology.”**
???? https://lnkd.in/eKZ5MQmK
The paper pulls no punches:
- CCR5 is no longer just an HIV co-receptor.
- The CCL5/CCR5 axis is a **master regulator in oncology**, driving leukocyte recruitment, tumor progression, angiogenesis, metastasis, immune evasion, and therapy resistance.
- Blocking CCR5 is highlighted as a promising therapeutic strategy — with synergy alongside immune checkpoint inhibitors.
Here’s why this matters:
For decades, CCR5 was pigeonholed in infectious disease. Now, peer-reviewed science is validating it as a **macromolecular game-changer in cancer biology**. That is a narrative shift with enormous implications for oncology, immunology, and drug development.
The paper mentions CCR5 antagonists like Maraviroc, Vicriviroc, and Cenicriviroc. But here’s the key: only one CCR5 antagonist has generated broad *human clinical data in oncology and immunotherapy synergy* — **Leronlimab**.
This moment feels like the science is finally catching up to what some of us have been saying for years: CCR5 isn’t a side note. It’s a central node. And it may hold the keys to unlocking new strategies against cancer and immune-driven disease.
The field is wide open. The question now is: who will seize it?
Michael Fumelle
·
October 1 at 9:54 AM
·
Geoffrey Fourqurean’s Post from LinkedIn
View profile for Geoffrey Fourqurean
Geoffrey Fourqurean
Neuroscientist, Returned Peace Corps Volunteer, Polyglot, poet, Alumnus: AstraZeneca, GlaxoSmithKline, Neurocrine Biosciences, ex-Gilead, Chief Consultant, Patient Advocate, Biotech Industry Analyst, ESMO Member, Author
1d
A major new review just landed in the *International Journal of Biological Macromolecules* — and it’s a big deal.
Title: **“C–C motif glycoprotein ligand 5 (CCL5) and its GPCR CCR5: Macromolecular game-changers in cancer biology.”**
???? https://lnkd.in/eKZ5MQmK
The paper pulls no punches:
- CCR5 is no longer just an HIV co-receptor.
- The CCL5/CCR5 axis is a **master regulator in oncology**, driving leukocyte recruitment, tumor progression, angiogenesis, metastasis, immune evasion, and therapy resistance.
- Blocking CCR5 is highlighted as a promising therapeutic strategy — with synergy alongside immune checkpoint inhibitors.
Here’s why this matters:
For decades, CCR5 was pigeonholed in infectious disease. Now, peer-reviewed science is validating it as a **macromolecular game-changer in cancer biology**. That is a narrative shift with enormous implications for oncology, immunology, and drug development.
The paper mentions CCR5 antagonists like Maraviroc, Vicriviroc, and Cenicriviroc. But here’s the key: only one CCR5 antagonist has generated broad *human clinical data in oncology and immunotherapy synergy* — **Leronlimab**.
This moment feels like the science is finally catching up to what some of us have been saying for years: CCR5 isn’t a side note. It’s a central node. And it may hold the keys to unlocking new strategies against cancer and immune-driven disease.
The field is wide open. The question now is: who will seize it?
(4)
(0)